IP10 levels refine severity prognostication in COVID-19 and implicate causes of clinical deterioration: lessons for pandemic preparedness

IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies

IMU Biosciences joins NVIDIA Inception Programme to Accelerate AI-Driven Precision Medicine

IMU Biosciences expands leadership team with appointment of industry experts Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer